A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Xarelto – Rivaroxaban

  • Rivaroxaban (Xarelto): FDA Advisory Board Recommends Against Approval for Atrial Fibrillation

    Surprise to many people today:  An FDA staff report released today (Sept 6th, 2011) states that FDA reviewers recommend against the approval of rivaroxaban (Xarelto) for the atrial fibrillation indication.  A detailed discussion with reasons for the recommendation can be found here.  The main reason: It has not been shown that rivaroxaban is as effective as…

  • Apixaban (Eliquis) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new oral anticoagulants in development – Apixaban (Eliquis). Data from the large ARISTOTLE trial were published today in the NEJM, showing that in patients with atrial fibrillation Apixaban was more effective in preventing stroke and systemic thromboembolism, caused less major bleeding, and resulted…

  • Eliquis (Apixaban) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new blood thinners in development – Apixaban (Eliquis). Data from the large atrial fibrillation trial called ARISTOTLE were published today and show that the drug is more effective and safer than warfarin in patients with atrial fibrillation [ref 1].  This…

  • Xarelto (Rivaroxaban) – FDA Approved

    Today the FDA approved the oral anticoagulant Xarelto (rivaroxaban) for DVT prevention in patients undergoing knee or hip replacement surgery.  This is good news

  • Xarelto (Rivaroxaban) – FDA Approved

    On July 1st, the FDA approved the oral blood thinner Xarelto (rivaroxaban) for the prevention of deep vein thrombosis (DVT) in patients undergoing  knee or hip replacement surgery.

  • Xarelto® – Good News

    Summary Good news. A major study published in December 2010 in the  New England Journal of Medicine (NEJM) shows that the new oral “blood thinner” Xarelto® (=Rivaroxaban) is (a) as safe and effective as warfarin in patients with acute DVT, and (b) is quite effective in preventing recurrent venous thromboembolism if taken longer-term, with an…